Streptococcus pneumoniae serotypes differ in clinical manifestations among adults. Indirect effects of pediatric use of pneumococcal conjugate vaccines (PCVs) affect rates of adult serotype-specific invasive pneumococcal disease (IPD). To characterize PCV effect on adult serotype patterns, we reviewed the literature for differences in proportions and incidence matching the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent PCV within specified geographic and time conditions. For adult IPD serotype distribution before widespread pediatric PCV7 use, the median differential between the 23 and 13 serotypes was 16.3% in the core analysis. After pediatric PCV7 adoption, the median differential was 24.4% (P < .003).The median differential in IPD incidence among adults was 5.6 cases per 100 000 population before pediatric PCV7 use and 6.4 afterward (P = .52). The differential for the serotypes in alternate vaccines helps explain recent national recommendations for one or both vaccines in various populations. These differences may widen further, with more extensive pediatric uptake of higher-valence PCVs.
Streptococcus pneumoniae is both a human commensal and pathogen. These bacteria are remarkable for their diversity of antigenically distinct capsules. At present, at least 94 serologically distinct capsules (ie, serotypes) have been identified [1] , with more likely to be recognized in the future.
These capsules help protect pneumococci from opsonophagocytosis. The serotype designations for the capsules are not merely a form of laboratory nomenclature, but have important clinical implications among adults. Among the serotypes, some are associated with an increased degree of disease severity [2] [3] [4] , an increased risk of invasiveness (eg, meningitis, bacteremia) [3, 5, 6] , or an elevated case-fatality ratio [7, 8] . Some serotypes are more likely to display antibiotic resistance [9] [10] [11] [12] , which may provide a selective advantage over other serotypes. Individual serotype prevalence can change over time or geography [9, 12, 13] , or between age bands or anatomic niches [13] [14] [15] [16] . Healthy adults may be colonized or infected by different serotypes than older, frail individuals or those with underlying medical conditions [3, 14] . Certain serotypes may be more likely to behave as opportunistic pathogens [2] .
In the past, vaccine developers selected serotypes for inclusion in vaccine formulations based on varying degrees of understanding of the most common or most pathologic serotypes circulating. The 14-valent pneumococcal polysaccharide vaccine (PPSV) was licensed in 1977 in the United States for people aged 50 years and older or those 2 years and older with certain underlying health conditions, expecting to target 70%-80% of IPD cases [17] [18] [19] , based on data from the United States, parts of Europe, and South Africa. Expansion to 23 serotypes (ie, PPSV23) was based on a broader global survey of invasive pneumococcal isolates coordinated by multiple national governments and the World Health Organization. Thus, PPSV23 was introduced in 1983 with serotypes covering about 88% of isolates from blood and cerebrospinal fluid from globally dispersed sites [19, 20] . In the mid-1990s, serotypes for various pediatric pneumococcal conjugate vaccine (PCV) formulations were based on other global serotype surveys [21, 22] .
Across the span of decades, individual serotypes have waxed and waned in prevalence among adults, largely due to innate microbiological characteristics, augmented by the pressures of antibiotic usage [9, 23] . In our present era, another humaninduced phenomenon has manifested. The direct and indirect effects of widespread pediatric use of PCVs have substantially influenced the relative frequency of pneumococcal disease among children as well as adults, due in part to reductions in pediatric nasopharyngeal carriage. This article reviews these changes in frequency among adults, extending a preliminary report [24] .
METHODS
To identify peer-reviewed articles describing systematic surveillance of pneumococcal serotype distribution among adults, we searched the PubMed database. The search terms were [ pneumococcal infections/*epidemiology AND adult AND (serotyping OR bacterial typing techniques)]. This query yielded 455 titles. We also considered relevant articles identified from references cited in these articles, as well as national government surveillance reports.
The study bibliography was restricted according to the following criteria. Studies that reported results based on IPD from January 1995 to November 2013 were included if at least 150 isolates were typed for at least 20 serotypes or serogroups, with the 23-and 13-relevant serotypes distinguishable. Studies describing general populations of adults were included, focusing on cohorts of age ≥40 years; studies were accepted if agestratified results excluded patients younger than 5 years of age. Studies of manifestations solely of meningitis, otitis media, conjunctivitis, or endophthalmitis were excluded, as were studies describing only nasopharyngeal carriage or family transmission. Studies limited to special (eg, immunocompromised) cohorts were not included in this review. These criteria reduced the publication list to 52 relevant publications.
Among these 52 publications, several addressed the same catchment area in various time intervals. We assembled a core group of matched studies for this analysis, defined as those from the same catchment area with data both before widespread pediatric use of PCV was adopted and for an interval beginning at least 2 years after widespread pediatric use of PCV was adopted. Widespread pediatric PCV programs were defined here as those reaching at least 50% of a catchment area's children or funding for a region-wide vaccination program. Studies with surveillance during that 2-year window were excluded. Eligible studies from only one time period or the other were considered in a supplemental manner. Where several interval options were available for the same catchment area, studies of more recent time intervals were included and earlier studies excluded, to focus the analysis on serotype distributions shortly before PCV introduction or closer to our present time. Where multiple studies addressed overlapping segments of geography, studies involving larger catchment areas were selected and the others excluded.
To calculate differences in serotype distribution, the proportion of IPD isolates in included reports matching the pneumococcal serotypes in PPSV23 or PCV13 were transcribed or summed, and the differences calculated. The Descriptive statistics for sets of before or after studies were calculated, to assess ranges, medians, and 25th and 75th percentiles. Reports describing at least 20 serogroups without further subtyping [25] [26] [27] were adjusted proportionately based on similar reports that reported at least 30 specific strata of subtyping [28, 29] . Median values were compared with the 2-tailed Mann-Whitney U test, with α set at .05. For data available from the same source across multiple years, tests of linear trend compared the slope of regression lines to zero (horizontal) using the t statistic.
For reports describing IPD incidence (or notification) rates, differences in disease rates corresponding to the serotypes in PPSV23 or PCV13 were evaluated. If necessary, age-stratumspecific incidence rates were multiplied by corresponding proportions of IPD isolates. Descriptive statistics were determined, to calculate ranges, medians, and 25th and 75th percentiles.
RESULTS
Applying these inclusion and exclusion criteria, the core set of adult serotype-proportion studies encompassed 6 geographic areas (ie, England, France, Portugal, Australia, New Zealand, and United States), with matched data both before and after widespread adoption of pediatric PCV7 programs (Table 1) [5, 10, [29] [30] [31] [32] [33] [34] [35] [36] [37] . For proportions before widespread PCV7 use, the differentials between the 23 and the 13 vaccine serotypes in adults ranged from 8% to 20%. The 25th, 50th (median), and 75th percentiles were 11%, 16%, and 27%, respectively. For proportions after widespread PCV7 adoption, the differentials in adults ranged from 17% to 30%. The 25th, 50th, and 75th percentiles were 19%, 24%, and 27%, respectively. The difference in the medians for the 2 time periods was statistically significant (P < .0003, 2-tailed Mann-Whitney U test). A supplemental bibliography consisted of 16 adult serotypeproportion studies before widespread pediatric PCV7 programs and one study after adoption (Table 2) [25] [26] [27] [28] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] . This latter study involved primarily PCV7 usage, except for PCV13 for a few months [50] . For proportions in the supplemental adult studies before widespread pediatric PCV7 use, the differentials ranged from 0% to 28%. The 25th, 50th, and 75th percentiles were 11%, 14%, and 22%, respectively. The median value of 14% was not statistically different from the 16% value of the core analysis (P = .80). Three research groups providing the matched before/after adult data sets reported multiple differentials between the 23 and 13 vaccine serotypes across intervals of at least 8 years: England and Wales [5, 30, 51, 52] , France [31] , and the United States [10, 13, 37, 53] . As shown in Figure 1 , the English and French 23-vs-13 differentials increased in a statistically significant manner across the surveillance years (England and Wales, r 2 = 0.60, P = .005; France, r 2 = 0.71, P = .008). The US differentials, which included only 6 data points, showed a rising trend line without reaching statistical significance (r 2 = 0.22, P = .35). Table 3 displays the serotype proportions for adults in various broad or narrow age strata. In general, the 23-type, 13-type, and differential values from the core studies, the supplemental studies, and both groups combined differed by only a few percentage points. Where it was possible to calculate Mann-Whitney U statistics for the core studies, no statistically significant differences were found.
To assess age-specific and serotype-specific IPD incidence rates among adults, the core set encompassed 5 geographic areas (ie, England and Wales, France, Australia, New Zealand, United States), with matched before and after data (Table 4) [10, 13, 31, [33] [34] [35] [36] 51] . The differentials among adults between the 23 and the 13 vaccine serotypes before widespread pediatric use of PCV7 ranged from 0.4 to 10 cases of IPD per 100 000 population. For the age ≥65 years cohort, the 25th, 50th, and 75th percentiles were 3.0, 5.6, and 5.7 cases per 100 000 population, respectively, and somewhat less in the age 15-64 years cohort. After widespread pediatric use of PCV7, the differentials ranged from 1.1 to 7.0 cases of IPD per 100 000 population. For the age ≥65 years cohort, the 25th, 50th, and 75th percentiles were 5.7, 6.4, and 6.9 cases per 100 000 population, respectively, and somewhat less in the age 15-64 years cohort. The medians for the 2 time periods did not differ statistically overall (P = .52, 2-tailed Mann-Whitney U test), nor when the age ≥65 cohort was considered alone (P = .30).
The core incidence data were supplemented with 6 adult incidence studies from before widespread adoption of PCV7 programs and one study from afterward (Table 5) [25, 26, 40, 41, 43, 49, 54] . For the age ≥65 years strata described before widespread pediatric use of PCV7, the differentials between the 23 and the 13 vaccine serotypes ranged from 0.1 to 7.3 cases of IPD per 100 000 population. The 25th, 50th, and 75th percentiles were 0.4, 1.6, and 2.1 cases of IPD per 100 000 population, with similar values in the 40-to 64-year-old cohort. The median value of 1.6 cases per 100 000 was statistically different from the 5.6 cases per 100 000 value of the core analysis (P = .034), perhaps related in part to differences in case ascertainment.
DISCUSSION
The indirect effects of pediatric pneumococcal vaccination on reducing adult disease have been reported from multiple settings [5, 13, 32, 51, [54] [55] [56] [57] . This review adds to this understanding, by describing the extent and geographic breadth of a [31] ; and United States [10, 13, 37, 53] . Abbreviation: IPD, invasive pneumococcal disease. specific temporal aspect of these indirect effects: the widening differential in serotype proportions between the 23 or 13 serotypes corresponding to alternate vaccines. The median difference for adults in serotype relevance between PPSV23 and PCV13 increased significantly from 16% to 24% in the core studies (Table 1) , after PCVs were widely adopted among children in matched settings. Although columns in Tables 1-5 refer to 13 pneumococcal types, the data in all studies in all tables, except one study in Table 2 [50], came from the PCV7 era in those settings. It is plausible that the 23-vs-13 proportion differentials will increase as serotype coverage increases upon switching the routine childhood vaccine from PCV7 to PCV10 or PCV13 [51] .
Although the difference in proportions clearly widened in the core studies (Table 1) , the difference for incidence rates widened only slightly (Table 4) . This may be due to several geographical areas experiencing an increase in pediatric and adult disease due to non-PCV7 serotypes (notably serotype 19A) during the observation windows [13, 50, 54] . It remains to be seen whether the incidence-rate differential will widen further. If initial indications from the United States and England hold true [51, 58, 59] , the additional serotypes in the newer pediatric vaccines can indirectly suppress additional disease in adult populations and should lead to wider differentials over time.
It has long been known that individual pneumococcal serotypes can vary in frequency across time and space. The narrow interquartile ranges of the aggregate or composite proportion of the 23-and 13-serotype bundles are remarkable (Tables 1-3 ). This may reflect a dampening effect as more serotypes are summed toward the total number of isolates. The consistency in findings across this range of ecologic studies is reassuring, with respect to worldwide use of the current vaccines. On the other hand, the overall incidence rates showed remarkable variation across both the core and supplemental studies (Tables 4  and 5 ). This may reflect, in part, differences in case ascertainment. The 23-vs-13 differences, though, were less variable.
Inclusion of relevant serotypes in a vaccine formulation is a necessary first step toward vaccine utility. Even so, these differentials in serotype distribution or incidence rates must not be confused with measures of vaccine efficacy. PCV13 has been shown to prevent IPD and other forms of pneumococcal disease in children [60] , but not yet in adults. A randomized Abbreviations: IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine. a Sufficient studies were available to compare the core finding for the age ≥50 years cohort with the age ≥15 years cohort, P = .94 using 2-tailed Mann-Whitney U test. b Sufficient studies were available to compare the core finding for the age ≥50 years cohort with the age ≥15 years cohort, P = .86 using 2-tailed Mann-Whitney U test. Similarly, for age ≥15 vs 5-65, P = .94; and for age ≥50 vs 5-65, P = 1.00. trial of PCV13 vs saline placebo in preventing vaccine-type pneumococcal pneumonia in adults is under way [61, 62] . PPSV23 has been shown, repeatedly, to prevent IPD in adults [12, 63] . Efficacy trials of PPSVs have generated inconsistent findings for protection against pneumococcal pneumonia, related to inadequate sample size or imprecise diagnostic methods. Even so, in the recently refreshed meta-analysis from the Cochrane Collaboration, the odds ratio for definitive pneumococcal pneumonia (vaccine serotypes) was 0.13 (95% confidence interval [CI], .05-.38; n = 30 561) for an estimated vaccine effect of 87% [62] . Most of the PPSV23 clinical trials predate the ability to reliably diagnose nonbacteremic pneumococcal pneumonia, but a study of Japanese nursing-home residents that relied on urine antigen detection reported 64% efficacy (95% CI, 32%-81%) for PPSV23 against pneumococcal pneumonia [64] . The differences in proportions and incidence rates reported here are not findings of cause and effect, although the matched geographical approach was intended to minimize confounding. An important limitation of this review is that it reprises the findings of the cited studies as published, despite heterogeneity in settings and data collection methods. Even within and between the matched before/after geographical areas, methods of case ascertainment, speed of pediatric PCV uptake, extent of pediatric PCV coverage, and other parameters varied.
Three of the core datasets estimated national experiences with multiple time points using consistent data collection methods (Figure 1) . Two of the 3 settings showed statistically significant increasing trend lines for the difference in proportions of IPD isolates. The US trend line had the shallowest slope, the fewest data points, and no data points beyond 2009. Additional data points as time progresses will aid interpretation in each case. Initial US reports indicate that IPD due to the 6 new serotypes represented in the pediatric PCV13 vaccine began to decline among unvaccinated adults within 18 months [59, 65] , including a 61% reduction in IPD incidence for those Tables 1 and 2 supports recent national recommendations in the United States, Canada, the United Kingdom, Germany, and Australia to retain PPSV23 for most people at elevated risk [66] [67] [68] [69] [70] [71] . With multiple national recommendations calling for immunocompromised adults to receive PCV13 followed by PPSV23 [66-68, 70, 71] , PCV13 offers possible benefits of memory T-cell induction, whereas the 23-valent vaccine plays a key role as the only form of prophylaxis for the 11 serotypes that account for 24% of IPD in settings with widespread pediatric PCV7 programs.
Considering the important clinical implications of serotype variability (eg, severity, invasiveness, lethality) described in the introduction, differences in IPD incidence rates related to vaccine serotypes may be more meaningful than relative proportions of these serotypes. A forecasting model that assumed the indirect effects of PCV7 among US adults also apply to PCV13 calculated a reduction in IPD incidence from 39 to 25 cases per 100 000 between 2009 and 2020 among adults aged ≥65 years [72] .
IPD serotype distribution in adults is not necessarily the same as the serotype distribution for pneumococcal pneumonia, with recent studies variously finding or not finding concordance [4, 73, 74] . A fuller understanding of such differences awaits wider use of sensitive and specific means of diagnosing nonbacteremic pneumococcal pneumonia.
In summary, this review describes substantial and growing differences in target size for 2 pneumococcal vaccine formulations licensed for adults in many countries. Because all pneumococcal vaccines are directed at specific bundles of serotypes, clinicians and policy makers should consider these differences in relevance to circulating serotypes to which adults are vulnerable, to maximize the value provided to vaccine recipients. Pneumococcal serotype distributions should be monitored further, both in terms of years and regions. This is especially important as widespread use of PCV10 or PCV13 is adopted in pediatric populations.
Notes

